In this respect, animal studies showed that treatment of APP/PS1 AD mice with Edaravone intraperitoneal injection either before or after the onset of Aβ disposition reduced the plaque load in the brain, alleviated OS, and reduced downstream pathologies including neuroinflammation, synaptic dysfunction, and apoptosis, and ameliorated cognitive deficits in AD mice (Jiao, Yao, et al. 2015). This evidence concerns the gene PSEN1 and Alzheimer disease.